...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Intestinal research. >Prediction of Tumor Recurrence in Patients with Non-Gastric Gastrointestinal Stromal Tumors Following Resection according to the Modified National Institutes of Health Criteria
【24h】

Prediction of Tumor Recurrence in Patients with Non-Gastric Gastrointestinal Stromal Tumors Following Resection according to the Modified National Institutes of Health Criteria

机译：根据修改后的美国国立卫生研究院标准，对非胃胃肠道间质瘤切除术后的肿瘤复发进行预测

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aims Few studies have investigated the prognosis of non-gastric gastrointestinal stromal tumors (GISTs) under the modified National Institutes of Health (NIH) consensus criteria in Korea. This study aims to clarify the clinical usefulness of the modified NIH criteria for risk stratification. Methods From January 2000 through October 2012, 88 patients who underwent curative resection for primary GISTs were included in this study. The enrolled patients were stratified to predict recurrence by the original NIH criteria and modified NIH criteria. Results In all, 88 patients had non-gastric GISTs, including 82 and 6 patients with GISTs of the small intestine and colorectum, respectively. The mean age was 57.3±13.0 years, and the median follow-up duration was 3.40 years (range, 0.02-12.76 years). All patients who were placed in the intermediate-risk category according to the original NIH criteria were reclassified into the high-risk category according to the modified NIH criteria. Therefore, the proportion of cases in the intermediate-risk category declined to 0.0% from 25.0% (22/88), and the proportion of cases in the high-risk category increased to 43.2% (38/88) from 18.2% (16/88) under the modified NIH criteria. Among the 22 reclassified patients, 6 (27.3%) suffered a recurrence during the observational period, and the recurrence rate of high-risk category patients was 36.8% (14/38). Conclusions Patients in the high-risk category according to the modified NIH criteria had a high GIST recurrence rate. Therefore, the modified NIH criteria are clinically useful in selecting patients who need imatinib adjuvant chemotherapy after curative surgical resection.
机译：背景/目的在韩国修改后的美国国立卫生研究院（NIH）共识标准下，很少有研究调查非胃肠道间质瘤（GIST）的预后。本研究旨在阐明经修订的NIH标准对危险分层的临床实用性。方法自2000年1月至2012年10月，本研究纳入88例行原发性GIST根治性切除术的患者。通过原始NIH标准和修改后的NIH标准对入组患者进行分层，以预测复发。结果总共有88例患有非胃GIST的患者，其中分别有82例和6例患有小肠和结肠直肠的GIST。平均年龄为57.3±13.0岁，中位随访时间为3.40岁（范围为0.02-12.76岁）。根据原始的NIH标准将所有处于中危类别的患者根据修改后的NIH标准重新分类为高危类别。因此，中风险类别的案件比例从25.0％（22/88）下降到0.0％，高风险类别的案件比例从18.2％（16/16）增加到43.2％（38/88）。 / 88）。在重新分类的22例患者中，有6例（27.3％）在观察期内复发，高危类别患者的复发率为36.8％（14/38）。结论根据改良的NIH标准，高危类别患者的GIST复发率较高。因此，修改后的NIH标准在选择根治性手术切除后需要伊马替尼辅助化疗的患者方面具有临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号